You just read:

Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)

News provided by

Ultragenyx Pharmaceutical Inc. and Kyowa Kirin

17 May, 2018, 13:30 BST